Phase III study of AJG511 in patients with active ulcerative colitis

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222653

Enrollment

120

Registered

2014-11-14

Start date

2014-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

investigational material(s) Generic name etc : AJG511 INN of investigational material : budesonide Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with active ulcerative colitis

Exclusion criteria

Exclusion criteria: Patients with a history of allergic reaction to budesonide

Design outcomes

Primary

Measure	Time frame
Complete mucosal healing rate	—

Secondary

Measure	Time frame
remission rate	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026